Medical Care
Global Non-small Cell Lung Cancer Therapeutics Market Research Report 2025
- Sep 09, 25
- ID: 494593
- Pages: 74
- Figures: 77
- Views: 8
This report aims to provide a comprehensive presentation of the global market for Non-small Cell Lung Cancer Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-small Cell Lung Cancer Therapeutics.
The Non-small Cell Lung Cancer Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Non-small Cell Lung Cancer Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Non-small Cell Lung Cancer Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GlaxoSmithKline
Novartis
AstraZeneca
Roche
Bristol-Myers Squibb
Pfizer
Eli Lilly
Sanofi
Segment by Type
Alimta
Iressa
Avastin
Tarceva
Zykadia
Tagrisso
Xalkori
Cyramza
Opdivo
Alecensa
Segment by Application
Hospital
Clinic
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non-small Cell Lung Cancer Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The Non-small Cell Lung Cancer Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Non-small Cell Lung Cancer Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Non-small Cell Lung Cancer Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GlaxoSmithKline
Novartis
AstraZeneca
Roche
Bristol-Myers Squibb
Pfizer
Eli Lilly
Sanofi
Segment by Type
Alimta
Iressa
Avastin
Tarceva
Zykadia
Tagrisso
Xalkori
Cyramza
Opdivo
Alecensa
Segment by Application
Hospital
Clinic
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non-small Cell Lung Cancer Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-small Cell Lung Cancer Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Alimta
1.2.3 Iressa
1.2.4 Avastin
1.2.5 Tarceva
1.2.6 Zykadia
1.2.7 Tagrisso
1.2.8 Xalkori
1.2.9 Cyramza
1.2.10 Opdivo
1.3 Market by Application
1.3.1 Global Non-small Cell Lung Cancer Therapeutics Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Non-small Cell Lung Cancer Therapeutics Market Perspective (2020-2031)
2.2 Global Non-small Cell Lung Cancer Therapeutics Growth Trends by Region
2.2.1 Global Non-small Cell Lung Cancer Therapeutics Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Non-small Cell Lung Cancer Therapeutics Historic Market Size by Region (2020-2025)
2.2.3 Non-small Cell Lung Cancer Therapeutics Forecasted Market Size by Region (2026-2031)
2.3 Non-small Cell Lung Cancer Therapeutics Market Dynamics
2.3.1 Non-small Cell Lung Cancer Therapeutics Industry Trends
2.3.2 Non-small Cell Lung Cancer Therapeutics Market Drivers
2.3.3 Non-small Cell Lung Cancer Therapeutics Market Challenges
2.3.4 Non-small Cell Lung Cancer Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-small Cell Lung Cancer Therapeutics Players by Revenue
3.1.1 Global Top Non-small Cell Lung Cancer Therapeutics Players by Revenue (2020-2025)
3.1.2 Global Non-small Cell Lung Cancer Therapeutics Revenue Market Share by Players (2020-2025)
3.2 Global Non-small Cell Lung Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Non-small Cell Lung Cancer Therapeutics Revenue
3.4 Global Non-small Cell Lung Cancer Therapeutics Market Concentration Ratio
3.4.1 Global Non-small Cell Lung Cancer Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-small Cell Lung Cancer Therapeutics Revenue in 2024
3.5 Global Key Players of Non-small Cell Lung Cancer Therapeutics Head office and Area Served
3.6 Global Key Players of Non-small Cell Lung Cancer Therapeutics, Product and Application
3.7 Global Key Players of Non-small Cell Lung Cancer Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-small Cell Lung Cancer Therapeutics Breakdown Data by Type
4.1 Global Non-small Cell Lung Cancer Therapeutics Historic Market Size by Type (2020-2025)
4.2 Global Non-small Cell Lung Cancer Therapeutics Forecasted Market Size by Type (2026-2031)
5 Non-small Cell Lung Cancer Therapeutics Breakdown Data by Application
5.1 Global Non-small Cell Lung Cancer Therapeutics Historic Market Size by Application (2020-2025)
5.2 Global Non-small Cell Lung Cancer Therapeutics Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Non-small Cell Lung Cancer Therapeutics Market Size (2020-2031)
6.2 North America Non-small Cell Lung Cancer Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Non-small Cell Lung Cancer Therapeutics Market Size by Country (2020-2025)
6.4 North America Non-small Cell Lung Cancer Therapeutics Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Non-small Cell Lung Cancer Therapeutics Market Size (2020-2031)
7.2 Europe Non-small Cell Lung Cancer Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Non-small Cell Lung Cancer Therapeutics Market Size by Country (2020-2025)
7.4 Europe Non-small Cell Lung Cancer Therapeutics Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Non-small Cell Lung Cancer Therapeutics Market Size (2020-2031)
8.2 Asia-Pacific Non-small Cell Lung Cancer Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Non-small Cell Lung Cancer Therapeutics Market Size by Region (2020-2025)
8.4 Asia-Pacific Non-small Cell Lung Cancer Therapeutics Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Non-small Cell Lung Cancer Therapeutics Market Size (2020-2031)
9.2 Latin America Non-small Cell Lung Cancer Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Non-small Cell Lung Cancer Therapeutics Market Size by Country (2020-2025)
9.4 Latin America Non-small Cell Lung Cancer Therapeutics Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-small Cell Lung Cancer Therapeutics Market Size (2020-2031)
10.2 Middle East & Africa Non-small Cell Lung Cancer Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Non-small Cell Lung Cancer Therapeutics Market Size by Country (2020-2025)
10.4 Middle East & Africa Non-small Cell Lung Cancer Therapeutics Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GlaxoSmithKline
11.1.1 GlaxoSmithKline Company Details
11.1.2 GlaxoSmithKline Business Overview
11.1.3 GlaxoSmithKline Non-small Cell Lung Cancer Therapeutics Introduction
11.1.4 GlaxoSmithKline Revenue in Non-small Cell Lung Cancer Therapeutics Business (2020-2025)
11.1.5 GlaxoSmithKline Recent Development
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis Business Overview
11.2.3 Novartis Non-small Cell Lung Cancer Therapeutics Introduction
11.2.4 Novartis Revenue in Non-small Cell Lung Cancer Therapeutics Business (2020-2025)
11.2.5 Novartis Recent Development
11.3 AstraZeneca
11.3.1 AstraZeneca Company Details
11.3.2 AstraZeneca Business Overview
11.3.3 AstraZeneca Non-small Cell Lung Cancer Therapeutics Introduction
11.3.4 AstraZeneca Revenue in Non-small Cell Lung Cancer Therapeutics Business (2020-2025)
11.3.5 AstraZeneca Recent Development
11.4 Roche
11.4.1 Roche Company Details
11.4.2 Roche Business Overview
11.4.3 Roche Non-small Cell Lung Cancer Therapeutics Introduction
11.4.4 Roche Revenue in Non-small Cell Lung Cancer Therapeutics Business (2020-2025)
11.4.5 Roche Recent Development
11.5 Bristol-Myers Squibb
11.5.1 Bristol-Myers Squibb Company Details
11.5.2 Bristol-Myers Squibb Business Overview
11.5.3 Bristol-Myers Squibb Non-small Cell Lung Cancer Therapeutics Introduction
11.5.4 Bristol-Myers Squibb Revenue in Non-small Cell Lung Cancer Therapeutics Business (2020-2025)
11.5.5 Bristol-Myers Squibb Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Details
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Non-small Cell Lung Cancer Therapeutics Introduction
11.6.4 Pfizer Revenue in Non-small Cell Lung Cancer Therapeutics Business (2020-2025)
11.6.5 Pfizer Recent Development
11.7 Eli Lilly
11.7.1 Eli Lilly Company Details
11.7.2 Eli Lilly Business Overview
11.7.3 Eli Lilly Non-small Cell Lung Cancer Therapeutics Introduction
11.7.4 Eli Lilly Revenue in Non-small Cell Lung Cancer Therapeutics Business (2020-2025)
11.7.5 Eli Lilly Recent Development
11.8 Sanofi
11.8.1 Sanofi Company Details
11.8.2 Sanofi Business Overview
11.8.3 Sanofi Non-small Cell Lung Cancer Therapeutics Introduction
11.8.4 Sanofi Revenue in Non-small Cell Lung Cancer Therapeutics Business (2020-2025)
11.8.5 Sanofi Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-small Cell Lung Cancer Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Alimta
1.2.3 Iressa
1.2.4 Avastin
1.2.5 Tarceva
1.2.6 Zykadia
1.2.7 Tagrisso
1.2.8 Xalkori
1.2.9 Cyramza
1.2.10 Opdivo
1.3 Market by Application
1.3.1 Global Non-small Cell Lung Cancer Therapeutics Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Non-small Cell Lung Cancer Therapeutics Market Perspective (2020-2031)
2.2 Global Non-small Cell Lung Cancer Therapeutics Growth Trends by Region
2.2.1 Global Non-small Cell Lung Cancer Therapeutics Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Non-small Cell Lung Cancer Therapeutics Historic Market Size by Region (2020-2025)
2.2.3 Non-small Cell Lung Cancer Therapeutics Forecasted Market Size by Region (2026-2031)
2.3 Non-small Cell Lung Cancer Therapeutics Market Dynamics
2.3.1 Non-small Cell Lung Cancer Therapeutics Industry Trends
2.3.2 Non-small Cell Lung Cancer Therapeutics Market Drivers
2.3.3 Non-small Cell Lung Cancer Therapeutics Market Challenges
2.3.4 Non-small Cell Lung Cancer Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-small Cell Lung Cancer Therapeutics Players by Revenue
3.1.1 Global Top Non-small Cell Lung Cancer Therapeutics Players by Revenue (2020-2025)
3.1.2 Global Non-small Cell Lung Cancer Therapeutics Revenue Market Share by Players (2020-2025)
3.2 Global Non-small Cell Lung Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Non-small Cell Lung Cancer Therapeutics Revenue
3.4 Global Non-small Cell Lung Cancer Therapeutics Market Concentration Ratio
3.4.1 Global Non-small Cell Lung Cancer Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-small Cell Lung Cancer Therapeutics Revenue in 2024
3.5 Global Key Players of Non-small Cell Lung Cancer Therapeutics Head office and Area Served
3.6 Global Key Players of Non-small Cell Lung Cancer Therapeutics, Product and Application
3.7 Global Key Players of Non-small Cell Lung Cancer Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-small Cell Lung Cancer Therapeutics Breakdown Data by Type
4.1 Global Non-small Cell Lung Cancer Therapeutics Historic Market Size by Type (2020-2025)
4.2 Global Non-small Cell Lung Cancer Therapeutics Forecasted Market Size by Type (2026-2031)
5 Non-small Cell Lung Cancer Therapeutics Breakdown Data by Application
5.1 Global Non-small Cell Lung Cancer Therapeutics Historic Market Size by Application (2020-2025)
5.2 Global Non-small Cell Lung Cancer Therapeutics Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Non-small Cell Lung Cancer Therapeutics Market Size (2020-2031)
6.2 North America Non-small Cell Lung Cancer Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Non-small Cell Lung Cancer Therapeutics Market Size by Country (2020-2025)
6.4 North America Non-small Cell Lung Cancer Therapeutics Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Non-small Cell Lung Cancer Therapeutics Market Size (2020-2031)
7.2 Europe Non-small Cell Lung Cancer Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Non-small Cell Lung Cancer Therapeutics Market Size by Country (2020-2025)
7.4 Europe Non-small Cell Lung Cancer Therapeutics Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Non-small Cell Lung Cancer Therapeutics Market Size (2020-2031)
8.2 Asia-Pacific Non-small Cell Lung Cancer Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Non-small Cell Lung Cancer Therapeutics Market Size by Region (2020-2025)
8.4 Asia-Pacific Non-small Cell Lung Cancer Therapeutics Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Non-small Cell Lung Cancer Therapeutics Market Size (2020-2031)
9.2 Latin America Non-small Cell Lung Cancer Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Non-small Cell Lung Cancer Therapeutics Market Size by Country (2020-2025)
9.4 Latin America Non-small Cell Lung Cancer Therapeutics Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-small Cell Lung Cancer Therapeutics Market Size (2020-2031)
10.2 Middle East & Africa Non-small Cell Lung Cancer Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Non-small Cell Lung Cancer Therapeutics Market Size by Country (2020-2025)
10.4 Middle East & Africa Non-small Cell Lung Cancer Therapeutics Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GlaxoSmithKline
11.1.1 GlaxoSmithKline Company Details
11.1.2 GlaxoSmithKline Business Overview
11.1.3 GlaxoSmithKline Non-small Cell Lung Cancer Therapeutics Introduction
11.1.4 GlaxoSmithKline Revenue in Non-small Cell Lung Cancer Therapeutics Business (2020-2025)
11.1.5 GlaxoSmithKline Recent Development
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis Business Overview
11.2.3 Novartis Non-small Cell Lung Cancer Therapeutics Introduction
11.2.4 Novartis Revenue in Non-small Cell Lung Cancer Therapeutics Business (2020-2025)
11.2.5 Novartis Recent Development
11.3 AstraZeneca
11.3.1 AstraZeneca Company Details
11.3.2 AstraZeneca Business Overview
11.3.3 AstraZeneca Non-small Cell Lung Cancer Therapeutics Introduction
11.3.4 AstraZeneca Revenue in Non-small Cell Lung Cancer Therapeutics Business (2020-2025)
11.3.5 AstraZeneca Recent Development
11.4 Roche
11.4.1 Roche Company Details
11.4.2 Roche Business Overview
11.4.3 Roche Non-small Cell Lung Cancer Therapeutics Introduction
11.4.4 Roche Revenue in Non-small Cell Lung Cancer Therapeutics Business (2020-2025)
11.4.5 Roche Recent Development
11.5 Bristol-Myers Squibb
11.5.1 Bristol-Myers Squibb Company Details
11.5.2 Bristol-Myers Squibb Business Overview
11.5.3 Bristol-Myers Squibb Non-small Cell Lung Cancer Therapeutics Introduction
11.5.4 Bristol-Myers Squibb Revenue in Non-small Cell Lung Cancer Therapeutics Business (2020-2025)
11.5.5 Bristol-Myers Squibb Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Details
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Non-small Cell Lung Cancer Therapeutics Introduction
11.6.4 Pfizer Revenue in Non-small Cell Lung Cancer Therapeutics Business (2020-2025)
11.6.5 Pfizer Recent Development
11.7 Eli Lilly
11.7.1 Eli Lilly Company Details
11.7.2 Eli Lilly Business Overview
11.7.3 Eli Lilly Non-small Cell Lung Cancer Therapeutics Introduction
11.7.4 Eli Lilly Revenue in Non-small Cell Lung Cancer Therapeutics Business (2020-2025)
11.7.5 Eli Lilly Recent Development
11.8 Sanofi
11.8.1 Sanofi Company Details
11.8.2 Sanofi Business Overview
11.8.3 Sanofi Non-small Cell Lung Cancer Therapeutics Introduction
11.8.4 Sanofi Revenue in Non-small Cell Lung Cancer Therapeutics Business (2020-2025)
11.8.5 Sanofi Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Non-small Cell Lung Cancer Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Alimta
Table 3. Key Players of Iressa
Table 4. Key Players of Avastin
Table 5. Key Players of Tarceva
Table 6. Key Players of Zykadia
Table 7. Key Players of Tagrisso
Table 8. Key Players of Xalkori
Table 9. Global Non-small Cell Lung Cancer Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 10. Global Non-small Cell Lung Cancer Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 11. Global Non-small Cell Lung Cancer Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 12. Global Non-small Cell Lung Cancer Therapeutics Market Share by Region (2020-2025)
Table 13. Global Non-small Cell Lung Cancer Therapeutics Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 14. Global Non-small Cell Lung Cancer Therapeutics Market Share by Region (2026-2031)
Table 15. Non-small Cell Lung Cancer Therapeutics Market Trends
Table 16. Non-small Cell Lung Cancer Therapeutics Market Drivers
Table 17. Non-small Cell Lung Cancer Therapeutics Market Challenges
Table 18. Non-small Cell Lung Cancer Therapeutics Market Restraints
Table 19. Global Non-small Cell Lung Cancer Therapeutics Revenue by Players (2020-2025) & (US$ Million)
Table 20. Global Non-small Cell Lung Cancer Therapeutics Market Share by Players (2020-2025)
Table 21. Global Top Non-small Cell Lung Cancer Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-small Cell Lung Cancer Therapeutics as of 2024)
Table 22. Ranking of Global Top Non-small Cell Lung Cancer Therapeutics Companies by Revenue (US$ Million) in 2024
Table 23. Global 5 Largest Players Market Share by Non-small Cell Lung Cancer Therapeutics Revenue (CR5 and HHI) & (2020-2025)
Table 24. Global Key Players of Non-small Cell Lung Cancer Therapeutics, Headquarters and Area Served
Table 25. Global Key Players of Non-small Cell Lung Cancer Therapeutics, Product and Application
Table 26. Global Key Players of Non-small Cell Lung Cancer Therapeutics, Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Non-small Cell Lung Cancer Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 29. Global Non-small Cell Lung Cancer Therapeutics Revenue Market Share by Type (2020-2025)
Table 30. Global Non-small Cell Lung Cancer Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 31. Global Non-small Cell Lung Cancer Therapeutics Revenue Market Share by Type (2026-2031)
Table 32. Global Non-small Cell Lung Cancer Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 33. Global Non-small Cell Lung Cancer Therapeutics Revenue Market Share by Application (2020-2025)
Table 34. Global Non-small Cell Lung Cancer Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 35. Global Non-small Cell Lung Cancer Therapeutics Revenue Market Share by Application (2026-2031)
Table 36. North America Non-small Cell Lung Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. North America Non-small Cell Lung Cancer Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 38. North America Non-small Cell Lung Cancer Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 39. Europe Non-small Cell Lung Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 40. Europe Non-small Cell Lung Cancer Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 41. Europe Non-small Cell Lung Cancer Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 42. Asia-Pacific Non-small Cell Lung Cancer Therapeutics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 43. Asia-Pacific Non-small Cell Lung Cancer Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 44. Asia-Pacific Non-small Cell Lung Cancer Therapeutics Market Size by Region (2026-2031) & (US$ Million)
Table 45. Latin America Non-small Cell Lung Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Latin America Non-small Cell Lung Cancer Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 47. Latin America Non-small Cell Lung Cancer Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 48. Middle East & Africa Non-small Cell Lung Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 49. Middle East & Africa Non-small Cell Lung Cancer Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 50. Middle East & Africa Non-small Cell Lung Cancer Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 51. GlaxoSmithKline Company Details
Table 52. GlaxoSmithKline Business Overview
Table 53. GlaxoSmithKline Non-small Cell Lung Cancer Therapeutics Product
Table 54. GlaxoSmithKline Revenue in Non-small Cell Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 55. GlaxoSmithKline Recent Development
Table 56. Novartis Company Details
Table 57. Novartis Business Overview
Table 58. Novartis Non-small Cell Lung Cancer Therapeutics Product
Table 59. Novartis Revenue in Non-small Cell Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 60. Novartis Recent Development
Table 61. AstraZeneca Company Details
Table 62. AstraZeneca Business Overview
Table 63. AstraZeneca Non-small Cell Lung Cancer Therapeutics Product
Table 64. AstraZeneca Revenue in Non-small Cell Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 65. AstraZeneca Recent Development
Table 66. Roche Company Details
Table 67. Roche Business Overview
Table 68. Roche Non-small Cell Lung Cancer Therapeutics Product
Table 69. Roche Revenue in Non-small Cell Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 70. Roche Recent Development
Table 71. Bristol-Myers Squibb Company Details
Table 72. Bristol-Myers Squibb Business Overview
Table 73. Bristol-Myers Squibb Non-small Cell Lung Cancer Therapeutics Product
Table 74. Bristol-Myers Squibb Revenue in Non-small Cell Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 75. Bristol-Myers Squibb Recent Development
Table 76. Pfizer Company Details
Table 77. Pfizer Business Overview
Table 78. Pfizer Non-small Cell Lung Cancer Therapeutics Product
Table 79. Pfizer Revenue in Non-small Cell Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 80. Pfizer Recent Development
Table 81. Eli Lilly Company Details
Table 82. Eli Lilly Business Overview
Table 83. Eli Lilly Non-small Cell Lung Cancer Therapeutics Product
Table 84. Eli Lilly Revenue in Non-small Cell Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 85. Eli Lilly Recent Development
Table 86. Sanofi Company Details
Table 87. Sanofi Business Overview
Table 88. Sanofi Non-small Cell Lung Cancer Therapeutics Product
Table 89. Sanofi Revenue in Non-small Cell Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 90. Sanofi Recent Development
Table 91. Research Programs/Design for This Report
Table 92. Key Data Information from Secondary Sources
Table 93. Key Data Information from Primary Sources
Table 94. Authors List of This Report
List of Figures
Figure 1. Non-small Cell Lung Cancer Therapeutics Picture
Figure 2. Global Non-small Cell Lung Cancer Therapeutics Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Non-small Cell Lung Cancer Therapeutics Market Share by Type: 2024 VS 2031
Figure 4. Alimta Features
Figure 5. Iressa Features
Figure 6. Avastin Features
Figure 7. Tarceva Features
Figure 8. Zykadia Features
Figure 9. Tagrisso Features
Figure 10. Xalkori Features
Figure 11. Cyramza Features
Figure 12. Opdivo Features
Figure 13. Global Non-small Cell Lung Cancer Therapeutics Market Size by Application (2020-2031) & (US$ Million)
Figure 14. Global Non-small Cell Lung Cancer Therapeutics Market Share by Application: 2024 VS 2031
Figure 15. Hospital Case Studies
Figure 16. Clinic Case Studies
Figure 17. Non-small Cell Lung Cancer Therapeutics Report Years Considered
Figure 18. Global Non-small Cell Lung Cancer Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 19. Global Non-small Cell Lung Cancer Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 20. Global Non-small Cell Lung Cancer Therapeutics Market Share by Region: 2024 VS 2031
Figure 21. Global Non-small Cell Lung Cancer Therapeutics Market Share by Players in 2024
Figure 22. Global Top Non-small Cell Lung Cancer Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-small Cell Lung Cancer Therapeutics as of 2024)
Figure 23. The Top 10 and 5 Players Market Share by Non-small Cell Lung Cancer Therapeutics Revenue in 2024
Figure 24. North America Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. North America Non-small Cell Lung Cancer Therapeutics Market Share by Country (2020-2031)
Figure 26. United States Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Canada Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Europe Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Europe Non-small Cell Lung Cancer Therapeutics Market Share by Country (2020-2031)
Figure 30. Germany Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. France Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. U.K. Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Italy Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Russia Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Nordic Countries Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Asia-Pacific Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Asia-Pacific Non-small Cell Lung Cancer Therapeutics Market Share by Region (2020-2031)
Figure 38. China Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Japan Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. South Korea Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Southeast Asia Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. India Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Australia Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Latin America Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Latin America Non-small Cell Lung Cancer Therapeutics Market Share by Country (2020-2031)
Figure 46. Mexico Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Brazil Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Middle East & Africa Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Middle East & Africa Non-small Cell Lung Cancer Therapeutics Market Share by Country (2020-2031)
Figure 50. Turkey Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. Saudi Arabia Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 52. UAE Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 53. GlaxoSmithKline Revenue Growth Rate in Non-small Cell Lung Cancer Therapeutics Business (2020-2025)
Figure 54. Novartis Revenue Growth Rate in Non-small Cell Lung Cancer Therapeutics Business (2020-2025)
Figure 55. AstraZeneca Revenue Growth Rate in Non-small Cell Lung Cancer Therapeutics Business (2020-2025)
Figure 56. Roche Revenue Growth Rate in Non-small Cell Lung Cancer Therapeutics Business (2020-2025)
Figure 57. Bristol-Myers Squibb Revenue Growth Rate in Non-small Cell Lung Cancer Therapeutics Business (2020-2025)
Figure 58. Pfizer Revenue Growth Rate in Non-small Cell Lung Cancer Therapeutics Business (2020-2025)
Figure 59. Eli Lilly Revenue Growth Rate in Non-small Cell Lung Cancer Therapeutics Business (2020-2025)
Figure 60. Sanofi Revenue Growth Rate in Non-small Cell Lung Cancer Therapeutics Business (2020-2025)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Table 1. Global Non-small Cell Lung Cancer Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Alimta
Table 3. Key Players of Iressa
Table 4. Key Players of Avastin
Table 5. Key Players of Tarceva
Table 6. Key Players of Zykadia
Table 7. Key Players of Tagrisso
Table 8. Key Players of Xalkori
Table 9. Global Non-small Cell Lung Cancer Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 10. Global Non-small Cell Lung Cancer Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 11. Global Non-small Cell Lung Cancer Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 12. Global Non-small Cell Lung Cancer Therapeutics Market Share by Region (2020-2025)
Table 13. Global Non-small Cell Lung Cancer Therapeutics Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 14. Global Non-small Cell Lung Cancer Therapeutics Market Share by Region (2026-2031)
Table 15. Non-small Cell Lung Cancer Therapeutics Market Trends
Table 16. Non-small Cell Lung Cancer Therapeutics Market Drivers
Table 17. Non-small Cell Lung Cancer Therapeutics Market Challenges
Table 18. Non-small Cell Lung Cancer Therapeutics Market Restraints
Table 19. Global Non-small Cell Lung Cancer Therapeutics Revenue by Players (2020-2025) & (US$ Million)
Table 20. Global Non-small Cell Lung Cancer Therapeutics Market Share by Players (2020-2025)
Table 21. Global Top Non-small Cell Lung Cancer Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-small Cell Lung Cancer Therapeutics as of 2024)
Table 22. Ranking of Global Top Non-small Cell Lung Cancer Therapeutics Companies by Revenue (US$ Million) in 2024
Table 23. Global 5 Largest Players Market Share by Non-small Cell Lung Cancer Therapeutics Revenue (CR5 and HHI) & (2020-2025)
Table 24. Global Key Players of Non-small Cell Lung Cancer Therapeutics, Headquarters and Area Served
Table 25. Global Key Players of Non-small Cell Lung Cancer Therapeutics, Product and Application
Table 26. Global Key Players of Non-small Cell Lung Cancer Therapeutics, Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Non-small Cell Lung Cancer Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 29. Global Non-small Cell Lung Cancer Therapeutics Revenue Market Share by Type (2020-2025)
Table 30. Global Non-small Cell Lung Cancer Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 31. Global Non-small Cell Lung Cancer Therapeutics Revenue Market Share by Type (2026-2031)
Table 32. Global Non-small Cell Lung Cancer Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 33. Global Non-small Cell Lung Cancer Therapeutics Revenue Market Share by Application (2020-2025)
Table 34. Global Non-small Cell Lung Cancer Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 35. Global Non-small Cell Lung Cancer Therapeutics Revenue Market Share by Application (2026-2031)
Table 36. North America Non-small Cell Lung Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. North America Non-small Cell Lung Cancer Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 38. North America Non-small Cell Lung Cancer Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 39. Europe Non-small Cell Lung Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 40. Europe Non-small Cell Lung Cancer Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 41. Europe Non-small Cell Lung Cancer Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 42. Asia-Pacific Non-small Cell Lung Cancer Therapeutics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 43. Asia-Pacific Non-small Cell Lung Cancer Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 44. Asia-Pacific Non-small Cell Lung Cancer Therapeutics Market Size by Region (2026-2031) & (US$ Million)
Table 45. Latin America Non-small Cell Lung Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Latin America Non-small Cell Lung Cancer Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 47. Latin America Non-small Cell Lung Cancer Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 48. Middle East & Africa Non-small Cell Lung Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 49. Middle East & Africa Non-small Cell Lung Cancer Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 50. Middle East & Africa Non-small Cell Lung Cancer Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 51. GlaxoSmithKline Company Details
Table 52. GlaxoSmithKline Business Overview
Table 53. GlaxoSmithKline Non-small Cell Lung Cancer Therapeutics Product
Table 54. GlaxoSmithKline Revenue in Non-small Cell Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 55. GlaxoSmithKline Recent Development
Table 56. Novartis Company Details
Table 57. Novartis Business Overview
Table 58. Novartis Non-small Cell Lung Cancer Therapeutics Product
Table 59. Novartis Revenue in Non-small Cell Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 60. Novartis Recent Development
Table 61. AstraZeneca Company Details
Table 62. AstraZeneca Business Overview
Table 63. AstraZeneca Non-small Cell Lung Cancer Therapeutics Product
Table 64. AstraZeneca Revenue in Non-small Cell Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 65. AstraZeneca Recent Development
Table 66. Roche Company Details
Table 67. Roche Business Overview
Table 68. Roche Non-small Cell Lung Cancer Therapeutics Product
Table 69. Roche Revenue in Non-small Cell Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 70. Roche Recent Development
Table 71. Bristol-Myers Squibb Company Details
Table 72. Bristol-Myers Squibb Business Overview
Table 73. Bristol-Myers Squibb Non-small Cell Lung Cancer Therapeutics Product
Table 74. Bristol-Myers Squibb Revenue in Non-small Cell Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 75. Bristol-Myers Squibb Recent Development
Table 76. Pfizer Company Details
Table 77. Pfizer Business Overview
Table 78. Pfizer Non-small Cell Lung Cancer Therapeutics Product
Table 79. Pfizer Revenue in Non-small Cell Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 80. Pfizer Recent Development
Table 81. Eli Lilly Company Details
Table 82. Eli Lilly Business Overview
Table 83. Eli Lilly Non-small Cell Lung Cancer Therapeutics Product
Table 84. Eli Lilly Revenue in Non-small Cell Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 85. Eli Lilly Recent Development
Table 86. Sanofi Company Details
Table 87. Sanofi Business Overview
Table 88. Sanofi Non-small Cell Lung Cancer Therapeutics Product
Table 89. Sanofi Revenue in Non-small Cell Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 90. Sanofi Recent Development
Table 91. Research Programs/Design for This Report
Table 92. Key Data Information from Secondary Sources
Table 93. Key Data Information from Primary Sources
Table 94. Authors List of This Report
List of Figures
Figure 1. Non-small Cell Lung Cancer Therapeutics Picture
Figure 2. Global Non-small Cell Lung Cancer Therapeutics Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Non-small Cell Lung Cancer Therapeutics Market Share by Type: 2024 VS 2031
Figure 4. Alimta Features
Figure 5. Iressa Features
Figure 6. Avastin Features
Figure 7. Tarceva Features
Figure 8. Zykadia Features
Figure 9. Tagrisso Features
Figure 10. Xalkori Features
Figure 11. Cyramza Features
Figure 12. Opdivo Features
Figure 13. Global Non-small Cell Lung Cancer Therapeutics Market Size by Application (2020-2031) & (US$ Million)
Figure 14. Global Non-small Cell Lung Cancer Therapeutics Market Share by Application: 2024 VS 2031
Figure 15. Hospital Case Studies
Figure 16. Clinic Case Studies
Figure 17. Non-small Cell Lung Cancer Therapeutics Report Years Considered
Figure 18. Global Non-small Cell Lung Cancer Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 19. Global Non-small Cell Lung Cancer Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 20. Global Non-small Cell Lung Cancer Therapeutics Market Share by Region: 2024 VS 2031
Figure 21. Global Non-small Cell Lung Cancer Therapeutics Market Share by Players in 2024
Figure 22. Global Top Non-small Cell Lung Cancer Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-small Cell Lung Cancer Therapeutics as of 2024)
Figure 23. The Top 10 and 5 Players Market Share by Non-small Cell Lung Cancer Therapeutics Revenue in 2024
Figure 24. North America Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. North America Non-small Cell Lung Cancer Therapeutics Market Share by Country (2020-2031)
Figure 26. United States Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Canada Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Europe Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Europe Non-small Cell Lung Cancer Therapeutics Market Share by Country (2020-2031)
Figure 30. Germany Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. France Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. U.K. Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Italy Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Russia Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Nordic Countries Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Asia-Pacific Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Asia-Pacific Non-small Cell Lung Cancer Therapeutics Market Share by Region (2020-2031)
Figure 38. China Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Japan Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. South Korea Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Southeast Asia Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. India Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Australia Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Latin America Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Latin America Non-small Cell Lung Cancer Therapeutics Market Share by Country (2020-2031)
Figure 46. Mexico Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Brazil Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Middle East & Africa Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Middle East & Africa Non-small Cell Lung Cancer Therapeutics Market Share by Country (2020-2031)
Figure 50. Turkey Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. Saudi Arabia Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 52. UAE Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 53. GlaxoSmithKline Revenue Growth Rate in Non-small Cell Lung Cancer Therapeutics Business (2020-2025)
Figure 54. Novartis Revenue Growth Rate in Non-small Cell Lung Cancer Therapeutics Business (2020-2025)
Figure 55. AstraZeneca Revenue Growth Rate in Non-small Cell Lung Cancer Therapeutics Business (2020-2025)
Figure 56. Roche Revenue Growth Rate in Non-small Cell Lung Cancer Therapeutics Business (2020-2025)
Figure 57. Bristol-Myers Squibb Revenue Growth Rate in Non-small Cell Lung Cancer Therapeutics Business (2020-2025)
Figure 58. Pfizer Revenue Growth Rate in Non-small Cell Lung Cancer Therapeutics Business (2020-2025)
Figure 59. Eli Lilly Revenue Growth Rate in Non-small Cell Lung Cancer Therapeutics Business (2020-2025)
Figure 60. Sanofi Revenue Growth Rate in Non-small Cell Lung Cancer Therapeutics Business (2020-2025)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Spatial Metabolomics Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 04, 25
Global Pharmaceutical Process Analytical Technology (PAT) Software Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 04, 25
Global HASE Rheology Modifiers Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 04, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232